Cnbx Pharmaceuticals Inc. (CNBX)

Overview

CNBX Pharmaceuticals Inc. is a clinical stage pharmaceutical company focusing on the exploration, development, and potential market introduction of innovative cannabinoid-based items and technologies specifically targeting cancer treatment. Transitioning its name from Cannabics Pharmaceuticals Inc. in March 2022, the company has cemented its presence since its inception in 2004. Operating from its headquarters in Bethesda, Maryland, CNBX Pharmaceuticals harbors ambitions to push the boundaries of medical cannabis research to offer novel therapeutic alternatives for cancer patients. The endeavor to harness the medicinal properties of cannabinoids represents a cutting-edge approach to addressing the complex challenges faced by individuals battling cancer and related syndromes.

Products and Services

Cannabics SR
Developed as an oral capsule, Cannabics SR embodies the company’s leading edge in creating solutions for patients with advanced cancer and cancer anorexia cachexia syndrome. This product candidate leverages the therapeutic potentials of cannabinoids to provide relief and potentially improve quality of life.

PLP-33
Aimed at treating lateral spreading or sessile and colorectal polyps during colonoscopy procedures, PLP-33 is another tagline in CNBX Pharmaceuticals’ portfolio. The focus on such specific conditions exemplifies the company's dedication to addressing less targeted yet impactful areas of gastrointestinal health and cancer prevention.

BRST-33
Tailored towards the treatment of breast cancer, BRST-33 is in development to provide an alternative approach leveraging cannabinoid-based therapy. Highlighting its commitment to fighting one of the most common cancers affecting women globally, CNBX Pharmaceuticals aims to uncover new therapeutic avenues through this candidate.

MLN-33
With an eye on treating melanoma, MLN-33 represents the company's efforts in tackling this aggressive form of skin cancer. Through the exploration of cannabinoids' potential effects, CNBX aims to develop a novel therapeutic option for melanoma patients, contributing to broader cancer treatment strategies.

PRST-33
Focused on addressing prostate cancer, PRST-33 is another pivotal venture by CNBX Pharmaceuticals into utilizing cannabinoid compounds for cancer therapy. This project underscores the company's wide-ranging focus on various cancer types, striving to offer innovative solutions across the oncology spectrum.

RCC-33
RCC-33 constitutes an oral capsule formulation encapsulating cannabinoids for the potential treatment of colorectal cancer. This initiative reflects CNBX Pharmaceuticals’ commitment to broadening its product pipeline to encompass a wide array of cancer-related conditions, showcasing a direct approach towards integrating cannabinoid science in cancer therapy.

Cannabics CDx
An ex-vivo drug sensitivity test, Cannabics CDx, stands out as a service aiming to bridge personalized medicine with cannabinoid therapy. By assessing how individual cancer cells respond to cannabinoids, this tool endeavors to tailor treatments to the patient’s specific condition, enhancing the efficacy and targeting of cannabinoid-based cancer therapies.